Compare AWX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | PSTV |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 61.1M |
| IPO Year | 1998 | N/A |
| Metric | AWX | PSTV |
|---|---|---|
| Price | $2.60 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 10.9K | ★ 6.3M |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $79,712,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $28.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $0.16 |
| 52 Week High | $5.43 | $2.31 |
| Indicator | AWX | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 45.37 |
| Support Level | $2.55 | $0.61 |
| Resistance Level | $2.80 | $0.65 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.40 | 15.51 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).